RT Journal Article
T1 Gut and Endometrial Microbiome Dysbiosis: A New Emergent Risk Factor for Endometrial Cancer.
A1 Boutriq, Soukaina
A1 González-González, Alicia
A1 Plaza-Andrades, Isaac
A1 Laborda-Illanes, Aurora
A1 Sánchez-Alcoholado, Lidia
A1 Peralta-Linero, Jesús
A1 Domínguez-Recio, María Emilia
A1 Bermejo-Pérez, María José
A1 Lavado-Valenzuela, Rocío
A1 Alba, Emilio
A1 Queipo-Ortuño, María Isabel
K1 antitumour treatment
K1 dysbiosis
K1 endometrial cancer
K1 endometrial microbiome
K1 estrobolome
K1 estrogen metabolism
K1 gut microbiome
K1 inflammation
K1 prebiotics
K1 probiotics
AB Endometrial cancer is one of the most common gynaecological malignancies worldwide. Histologically, two types of endometrial cancer with morphological and molecular differences and also therapeutic implications have been identified. Type I endometrial cancer has an endometrioid morphology and is estrogen-dependent, while Type II appears with non-endometrioid differentiation and follows an estrogen-unrelated pathway. Understanding the molecular biology and genetics of endometrial cancer is crucial for its prognosis and the development of novel therapies for its treatment. However, until now, scant attention has been paid to environmental components like the microbiome. Recently, due to emerging evidence that the uterus is not a sterile cavity, some studies have begun to investigate the composition of the endometrial microbiome and its role in endometrial cancer. In this review, we summarize the current state of this line of investigation, focusing on the relationship between gut and endometrial microbiome and inflammation, estrogen metabolism, and different endometrial cancer therapies.
SN 2075-4426
YR 2021
FD 2021-07-14
LK https://hdl.handle.net/10668/26878
UL https://hdl.handle.net/10668/26878
LA en
DS RISalud
RD Apr 11, 2025